OS4.2 The long-term disease burden of meningioma patients: results on health-related quality of life, cognitive function, anxiety and depression

BACKGROUND: Recent systematic reviews reported that meningioma patients have an impaired health-related quality of life (HRQoL) and cognitive function up to 5 years after intervention. We aimed to assess the long-term disease burden of meningioma patients. MATERIAL AND METHODS: In this multicentre cross-sectional study, intracranial meningioma patients at least 5 years (median: 9.9 years) after anti-tumour therapy were included. HRQoL was measured with the generic SF-36 (8 scales and 2 component scores) and the disease-specific EORTC QLQ-BN20 (11 scales/items), and anxiety and depression with the Hospital Anxiety and Depression Scale (HADS: ≤11/21 points is indicative for probable anxiety or depression). Six domains of cognitive function were assessed with a standardised neuropsychological test battery (z-score